| Ytd | 42.86% | |
| 1y | -36.26% |
| Open | 1.11 | Prev Close | 1.10 | Low | 1.09 | High | 1.11 | Mkt Cap | 7.03M |
| Vol | 1.46K | Avg Vol | 246.88K | EPS | -0.21 | P/E | -5.30 | Forward P/E | -198.54 |
| Beta | 1.15 | Short Ratio | 1.18 | Inst. Own | 0.19% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-01 | 50-d Avg | 1.16 | 200-d Avg | 1.09 | 1yr Est | 4.69 |
IMRN News
MELBOURNE, Australia, July 16, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an
Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy Immuron is seeki
NEW YORK CITY, NY / ACCESS Newswire / April 22, 2026 / Emerging Growth Research today released a Fla
Sales Highlights (unaudited): Global Q3 sales AUD$1.5 million up 16% on prior comparative period (pc
NEW YORK CITY, NEW YORK / ACCESS Newswire / March 5, 2026 / Emerging Growth Research today released
NEW YORK CITY, NY / ACCESS Newswire / January 22, 2026 / Emerging Growth Research today released a F
Sales Highlights (unaudited): Global H1 sales AUD$4.2 million up 5% on prior comparative period (pcp
Key Points Immuron receives U.S. Food and Drug administration (FDA) approval for IMM-529 Investigati
New York, New York--(Newsfile Corp. - October 17, 2025) - Emerging Growth Research today announced t
Sales Highlights (unaudited): Global • Q1 sales AUD$2.0 million up 34% on prior comparative period (
Key Points Immuron submits Investigational new drug (IND) application to FDA for clinical developmen
Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced
MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) adv
Sales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior year June 2025 Qua
Highlights: Immuron on track to exceed A$7 million in Sales this financial year Uniformed Services U
Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highe
MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a
Sales Highlights: Global December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on p
Highlights: New Research Collaboration w ith Monash University One proposal will target Antimicrobia
Highlights: Travelan® (IMM-124E) Phase 2 Clinical Study Report submitted to the FDA Travelan® (IMM-1
Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the co
Shares of Porch Group, Inc. (NASDAQ: PRCH) rose sharply in pre-market trading after the company rep
On Thursday, 588 stocks hit new 52-week lows.
Gainers electroCore, Inc. (NASDAQ: ECOR) shares jumped 64% to settle at $0.88 on Wednesday after
Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares jumped 76.2% to $6.08.